Low-PV
Low-PV asked whether even low-risk patients gain from interferon: more of them stayed at the haematocrit target without progression when ropeginterferon was added to phlebotomy.
Overview
Low-PV randomised 127 patients with low-risk PV (under 60 with no prior thrombosis) to phlebotomy plus low-dose aspirin with or without ropeginterferon alfa-2b. At 12 months, 84 percent on ropeginterferon kept a haematocrit at or below 45 percent without progressive disease versus 60 percent with phlebotomy alone (Barbui and colleagues, Lancet Haematology 2021), with fewer phlebotomies and no excess serious harm; the benefit held at two years.
- 84 vs 60 out of 100 reached this endpoint at 12 months with Ropeginterferon + phlebotomy compared with Phlebotomy alone; 24 more per 100.
- Roughly one extra person helped for every 4 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- This endpoint is not one of the standard survival or response measures; read it alongside the trial's primary result.
- These results apply to the people the trial enrolled: Low-risk polycythaemia vera: ropeginterferon alfa-2b plus phlebotomy versus phlebotomy alone. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
127 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Response at 12 monthsprimary | Ropeginterferon + phlebotomy | 64 | 84% | - | - | - |
| Phlebotomy alone | 63 | 60% |
Similar pages
not linked directly; found by shared links- TermAquagenic pruritus
Shares Ropeginterferon alfa-2b, Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
- TermJAK2 V617F
Shares Ropeginterferon alfa-2b, Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
- TermErythrocytosis (primary vs secondary)
Shares Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
- TrialPROUD-PV and CONTINUATION-PV
Shares Ropeginterferon alfa-2b, Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
- TrialVERIFY
Shares Hepcidin-based control as first-line treatment in low-risk polycythaemia vera, Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
- IdeaClearing the JAK2 clone in polycythaemia vera: interferon plus mutant-selective inhibitors as a route to treatment-free remission
Shares Ropeginterferon alfa-2b, Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
- TrialRESPONSE-2
Shares Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
- TermHaematocrit
Shares Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.